Genetic, biochemical, and transcriptional responses of Saccharomyces cerevisiae to the novel immunomodulator FTY720 largely mimic those of the natural sphingolipid phytosphingosine.
Sphingolipids are signaling molecules that influence diverse cellular functions from control of the cell cycle to degradation of plasma membrane proteins. The synthetic sphingolipid-like compound FTY720 is an immunomodulating agent in clinical trials for transplant graft maintenance. In this report, we compare the effects of the natural yeast sphingolipid phytosphingosine with FTY720 in Saccharomyces cerevisiae. We show that the multicopy suppressor genes that induce growth resistance to FTY720 also confer resistance to growth-inhibitory concentrations of phytosphingosine. In addition, mutants for ubiquitination pathway proteins are shown to be resistant to the growth-inhibiting effect of both FTY720 and phytosphingosine. We observe fewer similarities between sphingosine and FTY720 than between FTY720 and phytosphingosine as revealed by genetic studies. Yeast cells lacking the specific sphingosine kinase LCB4 are sensitive to phytosphingosine and FTY720 but resistant to sphingosine, suggesting that FTY720 and phytosphingosine have a more related mechanism of action. Gene expression profile comparisons of sensitive and resistant yeast cells exposed to FTY720 and phytosphingosine highlight a number of similarities. In response to treatment with these compounds, approximately 77% of the genes that are regulated >2-fold by FTY720 also respond to phytosphingosine in the same direction in the parent strain. In addition, a close inspection of TAT1 and TAT2 transporters following exposure to phytosphingosine indicates that TAT1 protein is degraded in a similar fashion upon treatment with FTY720 and phytosphingosine. There were differences, however, with respect to the TAT2 protein level and the expression profiles of a subset of genes. The genetic, transcriptional, and biochemical data together indicate that FTY720 and phytosphingosine influence similar pathways in yeast cells. These findings offer further insights into the physiological pathways influenced by these compounds in all eukaryotic cells and help us to understand the therapeutic consequences of FTY720 in humans.
Welsch
Carole A
CA
Novartis Institute for Biomedical Research, Autoimmunity, and Transplantation, Novartis Pharma AG, CH-4002 Basel, Switzerland.
Roth
Lukas W A
LW
Goetschy
Jean François
JF
Movva
N Rao
NR
D000596:Amino Acids / Q000737:chemistry; D001692:Biological Transport; D002455:Cell Division; D002462:Cell Membrane / Q000378:metabolism; D003599:Cytoskeleton / Q000378:metabolism; D018076:DNA, Complementary / Q000378:metabolism; D015536:Down-Regulation; D004926:Escherichia coli / Q000378:metabolism; D000068876:Fingolimod Hydrochloride; D005838:Genotype; D015151:Immunoblotting; D007166:Immunosuppressive Agents / Q000494:pharmacology; D009154:Mutation; D020411:Oligonucleotide Array Sequence Analysis; D017853:Phosphotransferases (Alcohol Group Acceptor) / Q000737:chemistry; D010957:Plasmids / Q000378:metabolism; D016133:Polymerase Chain Reaction; D011409:Propylene Glycols / Q000737:chemistry*; D012313:RNA / Q000378:metabolism; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012441:Saccharomyces cerevisiae / Q000235:genetics / Q000378:metabolism*; D029701:Saccharomyces cerevisiae Proteins / Q000737:chemistry; D013107:Sphingolipids / Q000737:chemistry*; D013110:Sphingosine / Q000031:analogs & derivatives* / Q000737:chemistry* / Q000494:pharmacology; D014158:Transcription, Genetic; D015854:Up-Regulation
D000596:Amino Acids; D018076:DNA, Complementary; D007166:Immunosuppressive Agents; D011409:Propylene Glycols; D029701:Saccharomyces cerevisiae Proteins; D013107:Sphingolipids; D012313:RNA; C113962:LCB4 protein, S cerevisiae; D017853:Phosphotransferases (Alcohol Group Acceptor); D000068876:Fingolimod Hydrochloride; C012491:phytosphingosine; C061800:N,N-dimethylsphingosine; D013110:Sphingosine